Close Menu

NEW YORK – NuProbe and medical device/pharma firm Weigao Group have announced a strategic collaboration to use NuProbe's proprietary blocker displacement amplification (BDA) technology to develop a liquid biopsy next-generation sequencing panel for non-small cell lung cancer for the Chinese market.

The product will be compatible with available desktop NGS instruments, and competitive in terms of sensitivity, according to NuProbe. The partners plan to eventually apply for in vitro diagnostic (IVD) registration with China's National Medical Products Administration.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.